Open AccessDose-dependent Pharmacological Response to Rituximab in the Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculiti
Author(s) -
Jason Springer,
Ryan Funk
Publication year - 2021
Publication title -
the journal of rheumatology/journal of rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.577
H-Index - 178
eISSN - 1499-2752
pISSN - 0315-162X
DOI - 10.3899/jrheum.210361
Subject(s) - dosing , medicine , rituximab , regimen , trough concentration , gastroenterology , trough level , granulomatosis with polyangiitis , urology , pharmacology , vasculitis , transplantation , tacrolimus , disease , lymphoma
Rituximab (RTX) is effective in the induction and maintenance of remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, uncertainty remains regarding the optimal maintenance dosing regimen. This work evaluates the relationship between variability in RTX dosing and pharmacological response in AAV.